British Biotech Pharmaceuticals Limited

Alan Hastings Drummond

Andrew Paul Ayscough

Philip Huxley

Lindsey Ann Pearson

Lisa Marie Pratt

Cytostatic agents

The present invention provide compounds exemplified by 2(R or S)-&lsqb;2R-(S-Hydroxy-hydroxycarbamoyl-methyl)-4-methyl-pentanoylamine&rsqb;-2-phenyl-ethanoic acid cyclopentyl ester; 2(R or S)-(3S-Hydroxycarbamoyl-2R-isobutyl-hex-5-enoylamino)-2-phenylethanoic acid isopropyl ester; 2(R or S)-&lsqb;2R-(S-Hydroxycarbamoyi-methoxy-methyl)-4-methyl-pentanoylamino&rsqb;-3-phenylethanoic acid cyclopentyl ester; 2(R or S)-(3S-Hydroxycarbamoyl-2R-isobutyl-hex-5-enoylamino)-2-(4-methoxyphenyl)ethanoic acid cyclopentyl ester; 2(R or S)-(3S-Hydroxycarbamoyl-2R-isobutyl-hex-5-enoylamino)-2-(thien-2-yl)ethanoic acid cyclopentyl ester; and 2(R or S)-(3S-Hydroxycarbamoyl-2R-isobutyl-hex-5-enoylamino)-2-(thien-3-yl)ethanoic acid cyclopentyl ester are cytostatic agents. Methods of treating proliferative cell growth disorders as well a methods of inhibiting hyper-proliferative cells are also disclosed.

Growing community of inventors

Oxford, United Kingdom

Alan Hastings Drummond